207_Combined course Presentations

Tri als with Panitumumab/RT in anal cancer

Trial

N of patients

IMRT Regimen

Toxicity Efficacy

At 24 weeks 55% had CR

Feliu et al, ASCO 2014 GEMCAD 09-02

58

No 45 Gy + boost of 10-15 Gy

5-FU/MMC +RT + panitumumab

High 33/36 (92%) G3/4 AE